Evolus Q4 2025 prelim rev $88.6-90.6M (+12-15%); 2026 rev guide $327-337M; targets profitability

Evolus, Inc.

2025-FY EPS reported -$0.80 revenue$297,176,000

Preliminary Q4 2025 net revenue $88.6M-$90.6M, 12-15% YoY growth; positive non-GAAP op income $5M-$7M.
FY 2025 net revenue $295.5M-$297.5M, 11-12% YoY; Evolysse HA gels contributed ~8% of total revenue.
2026 guidance: net revenue $327M-$337M (11-13% growth); sustainable annual profitability commencing in 2026.
Updated 2028 long-term outlook: net revenue $450M-$500M (15-19% CAGR); non-GAAP op margin 13-15%.
Cash $53M at Dec 31, 2025, up from $43.5M at Sep 30, 2025, reflecting strong sales and expense management.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.